The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Preclinical efficacy of the combination of olaparib plus carboplatin with vandetanib in triple-negative breast cancer.
Nandini Dey
No relevant relationships to disclose
Hui Wu
No relevant relationships to disclose
Yuliang Sun
No relevant relationships to disclose
Pradip De
No relevant relationships to disclose
Brian Leyland-Jones
No relevant relationships to disclose